Brief: Adamis Pharmaceuticals Corp Says On April 12 Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
17/04/2023 21:49
April 17 (Reuters) - Adamis Pharmaceuticals Corp
ADMP.O :
* ADAMIS PHARMACEUTICALS CORP-ON APRIL 12 RECEIVED NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update